Malte peters morphosys

Author: jzwi

August undefined, 2024

Web31 aug. 2024 · MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that Malte Peters, M.D., the company's Chief Research and Development Officer and Management … WebMalte Peters, M.D. Chief Research and Development Officer Year of birth 1962 Nationality German Management Board Member of MorphoSys AG since 2024 End of current …

Tango Therapeutics Appoints Malte Peters, MD, to Board of …

Web5 jan. 2024 · MUNICH--(BUSINESS WIRE)--Der Aufsichtsrat der MorphoSys AG (Frankfurt Stock Exchange: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) hat Dr. Malte … Web13 dec. 2024 · Pelabresib im Falle einer Zulassung bei der schwierigen Behandlung von Myelofibrose haben könnte, sagte Forschungs- und Entwicklungsvorstand Malte Peters laut Mitteilung vom Sonntag. something went wrong outlook.com

MOR Stock Forecast, Price & News (MorphoSys) - MarketBeat

Web31 aug. 2024 · DGAP-News: MorphoSys AG / Schlagwort(e): Sonstiges MorphoSys ernennt Tim Demuth zum neuen Chief Research and Development Officer, Malte Peters … Web31 aug. 2024 · Malte joined MorphoSys in 2024. He was instrumental in building an accomplished Clinical Development organization that successfully developed and … WebMalte Peters, M.D., has served on our board of directors since September 2024. Since March 2024, Dr. Peters has served as Chief Research and Development Officer of … small coffee bar signs

Dr. Malte Peters wird neuer Chief Development Officer der …

WebMorphoSys首席研发官Malte Peters博士表示：“我们期待与天境生物一起推进TJ210/MOR210至临床研究阶段，并共同探索其作为晚期实体瘤患者新型治疗手段的潜力。根据协议，MorphoSys公司将从天境生物获得150万美元的里程碑付款。天境生物与MorphoSys于2024年11月签署了关于TJ210/MOR210的独家战略合作和区域许可协议 … Web3 nov. 2024 · In particular, those patients who fail standard treatments are in need of more therapeutic options. We look forward to working closely with the FDA and to develop MOR208 as a potential new treatment option for these patients as quickly as possible,” Malte Peters, MD, chief development officer of MorphoSys, said in a press release. something went wrong owaWeb5 jan. 2024 · MUNICH--(BUSINESS WIRE)--Der Aufsichtsrat der MorphoSys AG (Frankfurt Stock Exchange: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) hat Dr. Malte Peters zum neuen Chief Development Officer ernannt. something went wrong outlook couldn\u0027t set up

"Web5 jan. 2024 · Peters will take up the position on March 1, 2024 and will succeed Dr. Arndt Schottelius, who is... April 3, 2024 The supervisory board of MorphoSys AG has … " - Malte peters morphosys

Malte peters morphosys

Web31 aug. 2024 · MorphoSys ernennt Tim Demuth zum neuen Chief Research and Development Officer, Malte Peters geht in den Ruhestand ^ DGAP-News: MorphoSys AG / Schlagwort: Sonstiges MorphoSys ernennt Tim Demuth... 31 August 2024 Web1 mrt. 2024 · Malte Peters biography. Dr. Malte Peters is appointed as Chief Development Officer , Member of the Management Board of MorphoSys AG effectively from March 1, …

Did you know?

WebMalte Peters’ Post Malte Peters Physician, Drug Developer, Biopharma R&D Leader and Board Member 10mo Report ... morphosys.com 45 1 Comment ... Web31 aug. 2024 · 31.08.2024 - Das Biotechnologieunternehmen Morphosys bekommt einen neuen Forschungschef. Der amtierende Vorstand Malte Peters habe sich entschieden, …

Web10 okt. 2024 · CAMBRIDGE, Mass.--(BUSINESS WIRE)--Tango Therapeutics, a biotechnology company dedicated to delivering the next generation of targeted cancer … Web9 mei 2024 · My name is Julia Neugebauer, Director, Corporate Communicate and Investor Relations at MorphoSys. With me on the call today are Jean-Paul Kress, our Chief Executive Officer; Jens Holstein, our...

Web31 aug. 2024 · Malte joined MorphoSys in 2024. He was instrumental in building an accomplished Clinical Development organization that successfully developed and … WebMalte Peters Chief Development Officer at MorphoSys Location: Munich Area, Germany Add to My Lists Dr. Peters joined MorphoSys from Sandoz International, Holzkirchen, …

WebBeliebt bei Malte Peters Anmelden, um alle Aktivitäten zu sehen Berufserfahrung Board Member Tango Therapeutics Okt. 2024–Heute4 Jahre 6 Monate Cambridge, …

WebMalte Peters, M.D. joined MorphoSys AG in 2024 as Chief Development Officer and a member of the management board and was appointed Chief Research and Development … something went wrong outlook appWeb1 sep. 2024 · Munich - MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that Malte Peters, M.D., the company's Chief Research and Development Officer and … something went wrong outlook webWeb31 aug. 2024 · Officer, Malte Peters geht in den Ruhestand DGAP-News: MorphoSys AG / Schlagwort: Sonstiges MorphoSys ernennt Tim Demuth zum neuen Chief Research and Development Officer,... 1 September 2024 something went wrong pdf fileWebYou have not yet registered? Get your account for free. Register Here something went wrong pcWeb17 sep. 2024 · MorphoSys (FSE & NASDAQ: MOR) is a commercial-stage biopharmaceutical company dedicated to the discovery, development and commercialization of exceptional, innovative therapies for patients suffering from serious diseases. The … something went wrong peacockWeb1 sep. 2024 · Der 60-jährige Peters, der 2024 zu MorphoSys kam, werde mit dem Wechsel von sämtlichen operativen Aufgaben zurücktreten, hieß es weiter. Der promovierte … small coffee crossword clueWeb31 aug. 2024 · DGAP-News: MorphoSys AG / Key word(s): MiscellaneousMorphoSys appoints Tim Demuth as new Chief Research and Development Officer, following the … something went wrong perhaps a missing item